## 2 PHA in Biotechnology
### Drug Carriers
\begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Polymer** & **Producing Body** & **Application** & **Author Year** & **Refs.** \\ \hline PHV & _Bacillus cereus_ MCCB 281 & Drug carrier & [PERSON] et al., 2018 & [49] \\ P(3 HB)/P(3 HB-co-3 HV) & _Cupriavidus reactor_ DSM & & & \\
3 HV)/MCL-PHA & 428/_Pseudomonas_ & Scaffolds & [PERSON] et al., 2021 & [50] \\  & _chloropathis_ DSM 19603 & & & \\ PHB & _Azolobacter vinelandini_ & Tissue engineering & [PERSON] et al., 2017 & [51] \\ PHB & Unspecified & Scaffolds & [PERSON] et al., 2020 & [52] \\ PHB & Unspecified & Scaffolds & [PERSON] et al., 2022 & [53] \\ PHB & Unspecified & Scaffolds & [PERSON] et al., 2022 & [54] \\ P(3 HO-co-3 HHX) & Unspecified & Scaffolds & [PERSON] et al., 2017 & [55] \\ PHA & Unspecified & Scaffolds & Lizzarraga-Valderrama & [57] \\ PHB & Unspecified (commercial) & Tissue engineering & [PERSON] et al., 2018 & [58] \\ PHBVHHx & Unspecified & Scaffolds & [PERSON] et al., 2018 & [59] \\ PHA & _Pseudomonas aeruginosa_ & Tissue/carrier & [PERSON] et al., 2018 & [62] \\ PHB & ATCC 27853 & engineering & [PERSON] et al., 2018 & [62] \\ PHB & _Bacillus Cereus_ VIT-SSR1 & Drug carrier & [PERSON] et al., 2019 & [63] \\ PHB & Unspecified (commercial) & Drug carrier & [PERSON] et al., 2017 & [64] \\ PHB & _Pseudomonas aeruginosa_ & Drug carrier & [PERSON] et al., 2017 & [65] \\ SUB-1 & Drug carrier & [PERSON] et al., 2017 & [66] \\ PHBV & Unspecified & Drug carrier & [PERSON] et al., 2019 & [67] \\ PHA & Unspecified & Drug carrier & [PERSON] et al., 2021 & [68] \\ PHA & Unspecified & Drug carrier & [PERSON] et al., 2021 & [69] \\ PHA & Unspecified & Drug carrier & [PERSON] et al., 2017 & [70] \\ PHA & _Bacillus subtilis_ & Drug carrier & [PERSON] et al., 2018 & [71] \\ PHA & NCDC0671 & _Pseudomonas mendocin_ & Drug carrier & [PERSON] et al., 2021 & [72] \\ P(3 HO-co-3 HD)-co-3 HDD & CH50 & Drug carrier & [PERSON] et al., 2019 & [73] \\ poly(R-3-hydroxybutyrate-co-1,4-butylene adipate) & Unspecified & Drug carrier & [PERSON] et al., 2018 & [74] \\ PHBHHx & Unspecified & Drug carrier & [PERSON] et al., 2018 & [75] \\ P3 HB & Unspecified & Drug carrier & [PERSON] et al., 2021 & [76] \\ PHA & Unspecified & Drug carrier & [PERSON] et al., 2022 & [77] \\ PHB & Commercial of bacterial & Biomedical use & [PERSON] et al., 2018 & [78] \\ P(3 HV-co-3 HB) & _Halomonas_ sp. & Biomaterial & [PERSON] et al., 2021 & [79] \\ PHO & _Pseudomonas putida_ & Wound treatment & [PERSON] et al., 2023 & [80] \\  & _Pseudomonas mendecina_ & & & \\ P(3 HB)/P(3 HB-co-3 HD) & CH50 and _Bacillus subtilis_ & Wound treatment & [PERSON] et al., 2021 & [81] \\ PHA & _Pseudomonas chlororapphis_ & Adhesive & [PERSON] et al., 2018 & [82] \\  & subsp. _aurantiaca_ & Adhesive and biofilm & [PERSON] et al., 2018 & [83] \\ PHA & KT2440 & & [PERSON] et al., 2021 & [84] \\ P(3 HB)/P(3 HB/3 HV) & Unspecified & Herbicide carrier & [PERSON] et al., 2021 & [81] \\ \hline \hline \end{tabular}
\end{table} 
Table 1: \(Cont.\)The combination of PHB with chitosan resulted in a rigid matrix film, making drug carriers effective in releasing curcumin, a curcuminoid with anti-inflammatory, healing, and antioxidant properties widely used in the formulation of drugs [63]. Curcumin was also used in the work carried out by [PERSON] et al. [64], where PHB nanoparticles were combined with a gelatin matrix to form a nanocomposite, being tested for the loading of curcumin, a hydrophobic drug, and naproxen sodium, a nonsteroidal and hydrophilic anti-inflammatory drug, with curcumin being carried by the PHB. In contrast, naproxen sodium was solubilized in the gelatinous matrix. This combination of the double release of drugs was favorable and has shown that a cheap, sustainable, and straightforward approach is practical for hydrophobic and hydrophilic drugs. Drug release was reported using PHA produced by _Pseudomonas aeruginosa_, being loaded with curcumin in spherical nanoparticles with sizes between 300 and 500 nm, releasing the drug constantly for more than 5 h [65]. [PERSON] et al.